Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29775344 | 0.95 | CYP11B1 (0.54) | MKNK1MKNK2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL23326295 | 0.95 | CYP11B1 (0.54) | MKNK1MKNK2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL29775418 | 0.93 | CYP11B1 (0.57) | MKNK1MKNK2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL23326199 | 0.93 | CYP11B1 (0.57) | MKNK1MKNK2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL23326187 | 0.92 | MKNK1 (0.56) | MKNK1MKNK2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL29775420 | 0.92 | MKNK1 (0.56) | MKNK1MKNK2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL26473067 | 0.85 | MAPT (0.51) | MKNK1MKNK2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL26473138 | 0.83 | CYP11B1 (0.54) | MKNK1MKNK2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL23326266 | 0.81 | NPC1 (0.47) | MKNK1MKNK2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL28225240 | 0.80 | MKNK1 (0.60) | MKNK1MKNK2CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761083-B | 5-HT for treating depression 2A Agonists | 罗福拉公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-3962601-B1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2023-05-31 | — | — | EP | disclosed |
| EP-3962601-B1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2023-05-31 | — | — | EP | disclosed |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-05-09 | — | — | US | disclosed |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-05-09 | — | — | US | disclosed |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-05-09 | — | — | US | disclosed |
| US-11633390-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-04-25 | — | — | US | disclosed |
| US-11633390-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2023-04-25 | — | — | US | disclosed |
| CN-114761083-A | 5-HT for the treatment of depression2AAgonists | 罗福拉公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220062257-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2022-03-03 | — | — | US | disclosed |
| US-20220062257-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2022-03-03 | — | — | US | disclosed |
| US-11246860-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2022-02-15 | — | — | US | disclosed |
| US-11246860-B2 | 5-HT2A agonists for use in treatment of depression | Lophora ApS (DK) | 2022-02-15 | — | — | US | disclosed |
| US-20210330658-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2021-10-28 | — | — | US | disclosed |
| US-20210330658-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2021-10-28 | — | — | US | disclosed |
| US-20210137908-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2021-05-13 | — | — | US | disclosed |
| US-20210137908-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | Lophora ApS (DK) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330658-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | MKNK1 3633/4885MKNK2 2436/4885CYP19A1 894/4885 |
| US-20220062257-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | MKNK1 3633/4885MKNK2 2436/4885CYP19A1 894/4885 |
| US-11642336-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | MKNK1 3633/4885MKNK2 2436/4885CYP19A1 894/4885 |
| US-20210137908-A1 | 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION | HTR2A, HTR2C, HTR5A | MKNK1 3633/4885MKNK2 2436/4885CYP19A1 894/4885 |
| US-11633390-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | MKNK1 3633/4885MKNK2 2436/4885CYP19A1 894/4885 |
| US-11246860-B2 | 5-HT2A agonists for use in treatment of depression | HTR2A, HTR2C, HTR5A | MKNK1 3633/4885MKNK2 2436/4885CYP19A1 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.